HC Wainwright reaffirmed their buy rating on shares of Viking Therapeutics Inc (NASDAQ:VKTX) in a research note released on Sunday. The firm currently has a $6.00 price objective on the stock.

VKTX has been the subject of a number of other research reports. Laidlaw dropped their target price on Viking Therapeutics from $20.00 to $10.00 and set a buy rating for the company in a report on Thursday, August 11th. Maxim Group set a $5.00 target price on Viking Therapeutics and gave the stock a buy rating in a report on Thursday, August 11th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Viking Therapeutics currently has a consensus rating of Buy and a consensus target price of $7.00.

Viking Therapeutics (NASDAQ:VKTX) opened at 1.28 on Friday. Viking Therapeutics has a 12 month low of $1.06 and a 12 month high of $7.14. The company’s 50-day moving average is $1.34 and its 200 day moving average is $1.40. The firm’s market cap is $24.67 million.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.02. Equities research analysts expect that Viking Therapeutics will post ($0.98) EPS for the current fiscal year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company has a portfolio of over five drug candidates under development. The Company’s lead clinical program, VK5211, is an orally available drug candidate for acute rehabilitation following non-elective hip fracture surgery.

5 Day Chart for NASDAQ:VKTX

Receive News & Ratings for Viking Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.